Anna Maria Cafro

2.7k total citations
33 papers, 390 citations indexed

About

Anna Maria Cafro is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Anna Maria Cafro has authored 33 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 14 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Anna Maria Cafro's work include Multiple Myeloma Research and Treatments (19 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Cancer Treatment and Pharmacology (8 papers). Anna Maria Cafro is often cited by papers focused on Multiple Myeloma Research and Treatments (19 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Cancer Treatment and Pharmacology (8 papers). Anna Maria Cafro collaborates with scholars based in Italy, Germany and Netherlands. Anna Maria Cafro's co-authors include Marco Montillo, Enrica Morra, Alessandra Tedeschi, Roberto Cairoli, Silvio Veronese, Giovanna D’Avanzo, Ester Pungolino, Bruno Brando, Michele Nichelatti and Valentina Rossi and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and British Journal of Haematology.

In The Last Decade

Anna Maria Cafro

32 papers receiving 380 citations

Peers

Anna Maria Cafro
Comparison fields: 5 of 51
  • Hematology 186
  • Oncology 165
  • Molecular Biology 131
  • Genetics 112
  • Pathology and Forensic Medicine 101
Replace Maria Dimou with:
Maria Dimou Greece
Monica Tozzi Italy
E. Dorey United Kingdom
Margaret M. Showel United States
Gradimir Janković Serbia
Michele Cimminiello Italy
Marco Cerrano Italy
Luc Meuleners Belgium
Anne Stidsholt Roug Denmark
A. Lakhani United Kingdom
Maria Dimou Greece View profile →
Citations per field, relative to Anna Maria Cafro
Anna Maria Cafro · 1×
Citations per year, relative to Anna Maria Cafro
Anna Maria Cafro · 1×

Countries citing papers authored by Anna Maria Cafro

Since Specialization
Citations

This map shows the geographic impact of Anna Maria Cafro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Maria Cafro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Maria Cafro more than expected).

Fields of papers citing papers by Anna Maria Cafro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Maria Cafro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Maria Cafro. The network helps show where Anna Maria Cafro may publish in the future.

Co-authorship network of co-authors of Anna Maria Cafro

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Maria Cafro. A scholar is included among the top collaborators of Anna Maria Cafro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Maria Cafro. Anna Maria Cafro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Myeloma's multiple morphologies
2023 ·SHILAP Revista de lepidopterología ·Silvia Cantoni, (unknown), Valentina Mancini, Anna Maria Cafro, Roberto Cairoli
1
2
Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma
2023 ·Blood ·Fredrik Schjesvold, Andrew Spencer, Yaël C. Cohen, Enrique M. Ocio, (unknown), Anna Maria Cafro, Natalie S. Callander, Jonathan L. Kaufman, Meera Mohan, Martin Wermke, (unknown), Rebecca Kan, (unknown), Gina M. Trabucco, (unknown), Romain Séchaud, Cornelia Quadt, Raghav Chawla, Marc S. Raab
3
3
Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis
2023 ·Blood ·(unknown), Mónica Galli, Laura París, (unknown), Chiara Pavoni, Silvia Mangiacavalli, (unknown), (unknown), Alessandra Pompa, Anna Maria Cafro, Sara Pezzatti, Stefano Crippa, Alessandro Rambaldi
2
4
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse
2020 ·British Journal of Haematology ·Vittorio Montefusco, Alessandro Corso, Mónica Galli, (unknown), Sara Pezzatti, (unknown), Francesca Patriarca, Filíppo Gherlinzoni, Renato Zambello, Simona Sammassimo, Magda Marcatti, Andrea Nozza, Claudia Crippa, Anna Maria Cafro, Luca Baldini, Paolo Corradini
7
5
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
2018 ·Leukemia ·Sara Bringhen, Roberto Mina, Anna Maria Cafro, Anna Marina Liberati, Stefano Spada, Angelo Belotti, Gianluca Gaïdano, Francesca Patriarca, Rossella Troia, Renato Fanin, Lorenzo De Paoli, Giuseppe Rossi, Alessandra Lombardo, Paola Bertazzoni, Antonio Palumbo, Pieter Sonneveld, Mario Boccadoro
34
6
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
2017 ·Leukemia ·Heinz Ludwig, Katja Weisel, Maria Teresa Petrucci, Xavier Leleu, Anna Maria Cafro, Laurent Garderet, Clemens Leitgeb, Robin Foà, Richard Greil, Ibrahim Yakoub‐Agha, Dirk Zboralski, S Vauléon, (unknown), (unknown), Anna Kruschinski, Kai Riecke, Matthias Baumann, Monika Engelhardt
60
7
Bortezomib/Cyclophosphamide/Dexamethasone Versus Lenalidomide/Cyclophosphamide/Dexamethasone in Multiple Myeloma Patients at First Relapse: Final Results of a Phase III Study
2017 ·Blood ·Vittorio Montefusco, Alessandro Corso, Mónica Galli, Elena Tagliabue, Sara Pezzatti, Francesca Patriarca, Filíppo Gherlinzoni, Renato Zambello, Simona Sammassimo, Magda Marcatti, Andrea Nozza, Claudia Crippa, Anna Maria Cafro, Luca Baldini, Paolo Corradini
2
8
A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients
2016 ·Blood ·Sara Bringhen, Valeria Magarotto, Anna Marina Liberati, Angelo Belotti, Alessandra Larocca, Milena Gilestro, Francesca Bonello, Gianluca Gaïdano, Paola Bertazzoni, Raffaella Stocchi, Rossella Ribolla, (unknown), Francesca Patriarca, Roberto Passera, Lorenzo De Paoli, Stefania Oliva, Anna Maria Cafro, Pieter Sonneveld, Antonio Palumbo, Mario Boccadoro
7
9
Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma
2014 ·Blood ·Heinz Ludwig, Katja Weisel, Maria Teresa Petrucci, Xavier Leleu, Anna Maria Cafro, (unknown), Niklas Zojer, Robin Foà, Richard Greil, Ibrahim Yakoub‐Agha, Anna Kruschinski, (unknown), Kai Riecke, Monika Engelhardt
7
10
Response‐adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression‐free survival in transplanted patients with multiple myeloma
2011 ·American Journal of Hematology ·Alessandro Corso, Mónica Galli, Silvia Mangiacavalli, Fausto Rossini, Andrea Nozza, Cristiana Pascutto, Vittorio Montefusco, Luca Baldini, Anna Maria Cafro, Claudia Crippa, (unknown), Paolo Corradini
8
11
Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects
2009 ·Leukemia Research ·Alessandro Corso, Patrizia Zappasodi, Luciana Barbarano, Maria Teresa Petrucci, Antonio Palumbo, Tommaso Caravita, Silvia Mangiacavalli, Anna Maria Cafro, Marzia Varettoni, Francesca Gay, Enrica Morra, Mario Lazzarino
10
12
Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia
2009 ·Leukemia Research ·Marco Montillo, Francesca Ricci, Alessandra Tedeschi, Anna Maria Cafro, Anna Maria Nosari, Michele Nichelatti, Laura Marbello, Enrica Morra
6
13
Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma
2009 ·Leukemia & lymphoma ·Alessandro Corso, Luciana Barbarano, Silvia Mangiacavalli, Mauro Spriano, Emilio Paolo Alessandrino, Anna Maria Cafro, Cristiana Pascutto, Marzia Varettoni, Paolo Bernasconi, Giovanni Grillo, Angelo Michele Carella, (unknown), Mario Lazzarino, Enrica Morra
13
14
Osteonecrosis of the Jaw in Patients with Multiple Myeloma Treated with Bisphosphonates: Definition and Management of the Risk Related to Zoledronic Acid
2008 ·Clinical Lymphoma & Myeloma ·Anna Maria Cafro, Luciana Barbarano, Anna Maria Nosari, Giovanna D’Avanzo, Michele Nichelatti, Michele Bibas, Domenico Gaglioti, (unknown), Francesco Riva, Alessandro Andriani
30
15
High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study
2007 ·Cancer Chemotherapy and Pharmacology ·Alessandra Tedeschi, Marco Montillo, Elena Strocchi, Anna Maria Cafro, (unknown), (unknown), Michele Nichelatti, Laura Marbello, Claudia Baratè, Carlo Maurizio Camaggi, Enrica Morra
14
16
Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma
2005 ·Bone Marrow Transplantation ·Alessandro Corso, Silvia Mangiacavalli, Annamaria Nosari, Carlo Castagnola, Patrizia Zappasodi, Anna Maria Cafro, C. Astori, Maurizio Bonfichi, Marzia Varettoni, C. Rusconi, (unknown), C. Pascutto, Enrica Morra, Mario Lazzarino, (unknown)
5
17
Purging "In Vivo" with Alemtuzumab (Campath-1H) before Autologous Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).
2005 ·Blood ·Marco Montillo, Alessandra Tedeschi, Roberto Cairoli, Sara Miqueleiz, Barbara Scarpati, Anna Maria Cafro, (unknown), (unknown), Silvio Veronese, Enrica Morra
1
18
Feasiblity of Autologous Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Sequential Fludarabine and Campath-1H.
2004 ·Blood ·Alessandra Tedeschi, Roberto Cairoli, Marco Montillo, Paola Marenco, Giovanni Grillo, Valentina Rossi, Anna Maria Cafro, (unknown), Enrica Morra
2
19
Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H
2003 ·Leukemia ·Marco Montillo, Alessandra Tedeschi, Valentina Rossi, Roberto Cairoli, Ester Pungolino, (unknown), Anna Maria Cafro, Giovanna D’Avanzo, (unknown), Bruno Brando, Barbara Scarpati, Silvio Veronese, Enrica Morra
34
20
Low risk of thrombosis in family members of patients with hyperhomocysteinaemia
2002 ·British Journal of Haematology ·Ida Martinelli, Paolo Bucciarelli, Maddalena L. Zighetti, Anna Maria Cafro, Pier Mannuccio Mannucci
4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Dimou Breakdown of academic impact, for papers by Monica Tozzi Breakdown of academic impact, for papers by E. Dorey Breakdown of academic impact, for papers by Margaret M. Showel Breakdown of academic impact, for papers by Gradimir Janković Breakdown of academic impact, for papers by Michele Cimminiello Breakdown of academic impact, for papers by Marco Cerrano Breakdown of academic impact, for papers by Luc Meuleners Breakdown of academic impact, for papers by Anne Stidsholt Roug Breakdown of academic impact, for papers by A. Lakhani
Rankless by CCL
2026